Abbott Exits Indian Industry Group: Fault Lines Showing?
Abbott’s unexpected decision to move out of the Organization of Pharmaceutical Producers of India (OPPI), the premier multinational industry body in India, has provided enough grist to the rumor mill to work overtime. Experts tell Scrip where the divisive issues may lie.
You may also be interested in...
India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.
It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.